FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
March 24, 2022
Recursion dazzled investors with a tantalizing pitch: We are a biotech scaling more like a tech company.
The potential to boost the scale and efficiency of drug development by automating wet labs and applying machine learning to the resulting data led investors to hand Recursion $502 million to take four drugs into phase 2 and advance six other programs up to the cusp of the clinic.
The company has advanced its internal pipeline while continuing business development activities.
Recent News
- Improving Women’s Health: MobileODT Joins Liger Medical
- Wasatch Health Announces Structured Capital Fund
- Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas, Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains
- Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
- Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
